{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:47:20Z","timestamp":1785646040196,"version":"3.56.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system characterized by immune-mediated demyelination and subsequent axonal injury and neurodegeneration. Traditionally, the pathogenesis of MS has been attributed primarily to autoreactive immune responses targeting myelin sheaths antigens. However, growing evidence highlights the role of neurotransmitter dysregulation, particularly involving glutamate, acetylcholine, and dopamine pathways, in the development and progression of MS. These alterations in neurotransmitter systems may be especially relevant to the emergence of neuropsychiatric manifestations, including psychosis, which appears to occur more frequently in individuals with MS than in the general population. Also, some of the medications used in MS treatment might cause psychosis itself. Despite increasing recognition of MS-associated psychosis (P-MS), its underlying mechanisms remain poorly understood. This narrative review aims to provide a comprehensive overview of this often underestimated and potentially underdiagnosed clinical phenomenon. The current literature was reviewed with regard to the prevalence and risk factors of P-MS, as well as proposed pathophysiological mechanisms, including inflammatory, neurochemical, and structural contributors. Clinical presentations and differential diagnostic considerations are also discussed. Furthermore, evidence-based strategies for the management of P-MS are examined, with emphasis on the importance of interdisciplinary collaboration between neurologists and psychiatrists. By synthesizing current knowledge, this review seeks to raise awareness of P-MS as a clinically significant comorbidity that warrants further research and improved diagnostic and therapeutic approaches.<\/jats:p>","DOI":"10.1007\/s00702-026-03180-6","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:26:44Z","timestamp":1778754404000},"page":"1193-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychosis in multiple sclerosis\u2014a narrative review of an underestimated, but clinically significant problem"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-1566","authenticated-orcid":false,"given":"Piotr","family":"Olejnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Menchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-0975","authenticated-orcid":false,"given":"Kaja","family":"Kasare\u0142\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"3180_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acschemneuro.2c00589","volume":"14","author":"E Akyuz","year":"2023","unstructured":"Akyuz E, Celik BR, Aslan FS et al (2023) Exploring the Role of Neurotransmitters in Multiple Sclerosis: An Expanded Review. ACS Chem Neurosci 14:527\u2013553. https:\/\/doi.org\/10.1021\/acschemneuro.2c00589","journal-title":"ACS Chem Neurosci"},{"key":"3180_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1212\/01.CON.0000466662.89908.e7","volume":"21","author":"DB Arciniegas","year":"2015","unstructured":"Arciniegas DB (2015) Psychosis. Continuum (N Y) 21:715\u2013736. https:\/\/doi.org\/10.1212\/01.CON.0000466662.89908.e7","journal-title":"Continuum (N Y)"},{"key":"3180_CR3","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/ijms18081760","volume":"18","author":"B Arneth","year":"2017","unstructured":"Arneth B (2017) Multiple Sclerosis and Schizophrenia. Int J Mol Sci 18:1760. https:\/\/doi.org\/10.3390\/ijms18081760","journal-title":"Int J Mol Sci"},{"key":"3180_CR4","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00296-013-2750-z","volume":"33","author":"SD Bhangle","year":"2013","unstructured":"Bhangle SD, Kramer N, Rosenstein ED (2013) Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int 33:1923\u20131932. https:\/\/doi.org\/10.1007\/s00296-013-2750-z","journal-title":"Rheumatol Int"},{"key":"3180_CR5","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0104","author":"ES Brown","year":"2001","unstructured":"Brown ES, Chandler PA (2001) Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion CNS Disord. https:\/\/doi.org\/10.4088\/PCC.v03n0104. 3:","journal-title":"Prim Care Companion CNS Disord"},{"key":"3180_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1081-1206(10)62858-X","volume":"83","author":"ES Brown","year":"1999","unstructured":"Brown ES, Khan DA, Nejtek VA (1999) The psychiatric side effects of corticosteroids. Annals of Allergy. Asthma Immunol 83:495\u2013504. https:\/\/doi.org\/10.1016\/S1081-1206(10)62858-X","journal-title":"Asthma Immunol"},{"key":"3180_CR7","doi-asserted-by":"publisher","unstructured":"Caligiore D, Schirripa A, Biggio M (2025) System-level hypothesis of dopamine imbalance in early multiple sclerosis. Front Neurol 16. https:\/\/doi.org\/10.3389\/fneur.2025.1653134","DOI":"10.3389\/fneur.2025.1653134"},{"key":"3180_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.msard.2016.12.012","volume":"12","author":"CR Camara-Lemarroy","year":"2017","unstructured":"Camara-Lemarroy CR, Ibarra-Yruegas BE, Rodriguez-Gutierrez R et al (2017) The varieties of psychosis in multiple sclerosis: A systematic review of cases. Mult Scler Relat Disord 12:9\u201314. https:\/\/doi.org\/10.1016\/j.msard.2016.12.012","journal-title":"Mult Scler Relat Disord"},{"key":"3180_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/schbul\/sbab105","volume":"48","author":"M Campana","year":"2022","unstructured":"Campana M, Strau\u00df J, M\u00fcnz S et al (2022) Cerebrospinal Fluid Pathologies in Schizophrenia-Spectrum Disorder\u2014A Retrospective Chart Review. Schizophr Bull 48:47\u201355. https:\/\/doi.org\/10.1093\/schbul\/sbab105","journal-title":"Schizophr Bull"},{"key":"3180_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ph14030238","volume":"14","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B et al (2021) Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals 14:238. https:\/\/doi.org\/10.3390\/ph14030238","journal-title":"Pharmaceuticals"},{"key":"3180_CR11","doi-asserted-by":"publisher","first-page":"e100075","DOI":"10.1136\/gpsych-2019-100075","volume":"32","author":"CM Carrillo de Albornoz Calahorro","year":"2019","unstructured":"Carrillo de Albornoz Calahorro CM, Navarrete Paez MI, Guerrero Jimenez M, Gutierrez Rojas L (2019) Successful treatment of psychosis induced by interferon alpha and ribavirin with paliperidone: first case reported. Gen Psychiatr 32:e100075. https:\/\/doi.org\/10.1136\/gpsych-2019-100075","journal-title":"Gen Psychiatr"},{"key":"3180_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/10408363.2022.2039591","volume":"59","author":"S Carta","year":"2022","unstructured":"Carta S, Ferraro D, Ferrari S et al (2022) Oligoclonal bands: clinical utility and interpretation cues. Crit Rev Clin Lab Sci 59:391\u2013404. https:\/\/doi.org\/10.1080\/10408363.2022.2039591","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3180_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R et al (2021) B cells in multiple sclerosis \u2014 from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17:399\u2013414. https:\/\/doi.org\/10.1038\/s41582-021-00498-5","journal-title":"Nat Rev Neurol"},{"key":"3180_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2019.06.001","volume":"34","author":"J Cheema","year":"2019","unstructured":"Cheema J, Huynh A-C, Prat SS (2019) Multiple Sclerosis and psychosis: A case report. Mult Scler Relat Disord 34:158\u2013161. https:\/\/doi.org\/10.1016\/j.msard.2019.06.001","journal-title":"Mult Scler Relat Disord"},{"key":"3180_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1176\/appi.psy.50.5.538","volume":"50","author":"Y-C Cheng","year":"2009","unstructured":"Cheng Y-C, Chen C-C, Ho A-S, Chiu N-Y (2009) Prolonged Psychosis Associated With Interferon Therapy in a Patient With Hepatitis C: Case Study and Literature Review. Psychosomatics 50:538\u2013542. https:\/\/doi.org\/10.1176\/appi.psy.50.5.538","journal-title":"Psychosomatics"},{"key":"3180_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.psc.2007.07.003","volume":"30","author":"LA Chwastiak","year":"2007","unstructured":"Chwastiak LA, Ehde DM (2007) Psychiatric Issues in Multiple Sclerosis. Psychiatr Clin North Am 30:803\u2013817. https:\/\/doi.org\/10.1016\/j.psc.2007.07.003","journal-title":"Psychiatr Clin North Am"},{"key":"3180_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pnpbp.2004.05.010","volume":"28","author":"E Davids","year":"2004","unstructured":"Davids E, Hartwig U, Gastpar M (2004) Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 28:743\u2013744. https:\/\/doi.org\/10.1016\/j.pnpbp.2004.05.010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3180_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1176\/jnp.11.1.51","volume":"11","author":"C Diaz-Olavarrieta","year":"1999","unstructured":"Diaz-Olavarrieta C, Cummings JL, Velazquez J, Garcia de al Cadena C (1999) Neuropsychiatric Manifestations of Multiple Sclerosis. J Neuropsychiatry Clin Neurosci 11:51\u201357. https:\/\/doi.org\/10.1176\/jnp.11.1.51","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3180_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis \u2013 a review. Eur J Neurol 26:27\u201340. https:\/\/doi.org\/10.1111\/ene.13819","journal-title":"Eur J Neurol"},{"key":"3180_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/IMCRJ.S157287","volume":"11","author":"A Enderami","year":"2018","unstructured":"Enderami A, Fouladi R, Hosseini SH (2018) First-episode psychosis as the initial presentation of multiple sclerosis: a case report. Int Med Case Rep J Volume 11:73\u201376. https:\/\/doi.org\/10.2147\/IMCRJ.S157287","journal-title":"Int Med Case Rep J Volume"},{"key":"3180_CR21","doi-asserted-by":"publisher","unstructured":"Ermakov E, Mednova I, Boiko A, Ivanova S (2025) Neuroinflammation in Schizophrenia: An Overview of Evidence and Implications for Pathophysiology. J Integr Neurosci 24. https:\/\/doi.org\/10.31083\/JIN27636","DOI":"10.31083\/JIN27636"},{"key":"3180_CR22","doi-asserted-by":"publisher","unstructured":"Fairless R, Bading H, Diem R (2021) Pathophysiological Ionotropic Glutamate Signalling in Neuroinflammatory Disease as a Therapeutic Target. Front Neurosci 15. https:\/\/doi.org\/10.3389\/fnins.2021.741280","DOI":"10.3389\/fnins.2021.741280"},{"key":"3180_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1192\/bjp.161.5.680","volume":"161","author":"A Feinstein","year":"1992","unstructured":"Feinstein A, Boulay G, Du, Ron MA (1992) Psychotic Illness in Multiple Sclerosis. Br J Psychiatry 161:680\u2013685. https:\/\/doi.org\/10.1192\/bjp.161.5.680","journal-title":"Br J Psychiatry"},{"key":"3180_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","volume":"162","author":"JM Fletcher","year":"2010","unstructured":"Fletcher JM, Lalor SJ, Sweeney CM et al (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162:1\u201311. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04143.x","journal-title":"Clin Exp Immunol"},{"key":"3180_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/WNF.0b013e3181f8d513","volume":"33","author":"YD Fragoso","year":"2010","unstructured":"Fragoso YD, Frota ERC, Lopes JS et al (2010) Severe Depression, Suicide Attempts, and Ideation During the Use of Interferon Beta by Patients With Multiple Sclerosis. Clin Neuropharmacol 33:312\u2013316. https:\/\/doi.org\/10.1097\/WNF.0b013e3181f8d513","journal-title":"Clin Neuropharmacol"},{"key":"3180_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10072-011-0712-3","volume":"33","author":"T Gabeli\u0107","year":"2012","unstructured":"Gabeli\u0107 T, Adamec I, Mr\u0111en A et al (2012) Psychotic reaction as a manifestation of multiple sclerosis relapse treated with plasma exchange. Neurol Sci 33:379\u2013382. https:\/\/doi.org\/10.1007\/s10072-011-0712-3","journal-title":"Neurol Sci"},{"key":"3180_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00406-008-2009-y","volume":"258","author":"W Gaebel","year":"2008","unstructured":"Gaebel W, Zielasek J (2008) The DSM-V initiative deconstructing psychosis in the context of Kraepelin\u2019s concept on nosology. Eur Arch Psychiatry Clin Neurosci 258:41\u201347. https:\/\/doi.org\/10.1007\/s00406-008-2009-y","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3180_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.31887\/DCNS.2015.17.1\/wgaebel","volume":"17","author":"W Gaebel","year":"2015","unstructured":"Gaebel W, Zielasek J (2015) Focus on psychosis. Dialogues Clin Neurosci 17:9\u201318. https:\/\/doi.org\/10.31887\/DCNS.2015.17.1\/wgaebel","journal-title":"Dialogues Clin Neurosci"},{"key":"3180_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","volume":"26","author":"M Gasim","year":"2018","unstructured":"Gasim M, Bernstein CN, Graff LA et al (2018) Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Mult Scler Relat Disord 26:124\u2013156. https:\/\/doi.org\/10.1016\/j.msard.2018.09.008","journal-title":"Mult Scler Relat Disord"},{"key":"3180_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.neurol.2024.03.009","volume":"180","author":"H Gauthier","year":"2024","unstructured":"Gauthier H, Zedet M, Wahab A et al (2024) Metabolic syndrome and the phenotype of multiple sclerosis. Rev Neurol (Paris) 180:673\u2013681. https:\/\/doi.org\/10.1016\/j.neurol.2024.03.009","journal-title":"Rev Neurol (Paris)"},{"key":"3180_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/NDT.S116772","volume":"13","author":"T Gilberthorpe","year":"2017","unstructured":"Gilberthorpe T, O\u2019Connell K, Carolan A et al (2017) The spectrum of psychosis in multiple sclerosis: a clinical case series. Neuropsychiatr Dis Treat Volume 13:303\u2013318. https:\/\/doi.org\/10.2147\/NDT.S116772","journal-title":"Neuropsychiatr Dis Treat Volume"},{"key":"3180_CR32","first-page":"111","volume":"44","author":"FC Goggans","year":"1983","unstructured":"Goggans FC, Weisberg LJ, Koran LM (1983) Lithium prophylaxis of prednisone psychosis: a case report. J Clin Psychiatry 44:111\u2013112","journal-title":"J Clin Psychiatry"},{"key":"3180_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1756285608100325","volume":"2","author":"IS Haussleiter","year":"2009","unstructured":"Haussleiter IS, Br\u00fcne M, Juckel G (2009) Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Ther Adv Neurol Disord 2:13\u201329. https:\/\/doi.org\/10.1177\/1756285608100325","journal-title":"Ther Adv Neurol Disord"},{"key":"3180_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","volume":"34","author":"J Howard","year":"2016","unstructured":"Howard J, Trevick S, Younger DS (2016) Epidemiology of Multiple Sclerosis. Neurol Clin 34:919\u2013939. https:\/\/doi.org\/10.1016\/j.ncl.2016.06.016","journal-title":"Neurol Clin"},{"key":"3180_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S (2009) The Dopamine Hypothesis of Schizophrenia: Version III\u2013The Final Common Pathway. Schizophr Bull 35:549\u2013562. https:\/\/doi.org\/10.1093\/schbul\/sbp006","journal-title":"Schizophr Bull"},{"key":"3180_CR36","unstructured":"Hrebicek K, Olinka MIN (2021) Identifying and treating steroid-induced psychosis in MS patients using quetiapine. In: Bethoux Francois (ed) Annual Meeting of the Consortium of Multiple Sclerosis Centers. Delaware Media Group, Glen Rock, USA, pp 15\u201316"},{"key":"3180_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/NDT.S268360","volume":"17","author":"Y-C Huang","year":"2021","unstructured":"Huang Y-C, Chien W-C, Chung C-H et al (2021) Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. Neuropsychiatr Dis Treat Volume 17:587\u2013604. https:\/\/doi.org\/10.2147\/NDT.S268360","journal-title":"Neuropsychiatr Dis Treat Volume"},{"key":"3180_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0269881107083997","volume":"22","author":"A Hussain","year":"2008","unstructured":"Hussain A, Belderbos S (2008) Risperidone depot in the treatment of psychosis associated with multiple sclerosis \u2014 a case report. J Psychopharmacol 22:925\u2013926. https:\/\/doi.org\/10.1177\/0269881107083997","journal-title":"J Psychopharmacol"},{"key":"3180_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/8755122520978534","volume":"37","author":"G Huynh","year":"2021","unstructured":"Huynh G, Reinert JP (2021) Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases. J Pharm Technol 37:120\u2013126. https:\/\/doi.org\/10.1177\/8755122520978534","journal-title":"J Pharm Technol"},{"key":"3180_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4274\/jmsr.galenos.2022.2022-8-1","volume":"2","author":"Y Inanc","year":"2022","unstructured":"Inanc Y, Kaya T (2022) Psychiatric Disorders in Multiple Sclerosis. J Multiple Scler Res 2:31\u201335. https:\/\/doi.org\/10.4274\/jmsr.galenos.2022.2022-8-1","journal-title":"J Multiple Scler Res"},{"key":"3180_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-024-02792-0","volume":"131","author":"KA Jellinger","year":"2024","unstructured":"Jellinger KA (2024) Depression and anxiety in multiple sclerosis. Review of a fatal combination. J Neural Transm 131:847\u2013869. https:\/\/doi.org\/10.1007\/s00702-024-02792-0","journal-title":"J Neural Transm"},{"key":"3180_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.neurol.2025.03.012","volume":"181","author":"I Ketata","year":"2025","unstructured":"Ketata I, Ellouz E, Ketata A (2025) Psychoses onset in multiple sclerosis: A systematic review and meta-analysis. Rev Neurol (Paris) 181:483\u2013502. https:\/\/doi.org\/10.1016\/j.neurol.2025.03.012","journal-title":"Rev Neurol (Paris)"},{"key":"3180_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","volume":"2","author":"GM Khandaker","year":"2015","unstructured":"Khandaker GM, Cousins L, Deakin J et al (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2:258\u2013270. https:\/\/doi.org\/10.1016\/S2215-0366(14)00122-9","journal-title":"Lancet Psychiatry"},{"key":"3180_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3988\/jcn.2023.0501","volume":"20","author":"JS Kim","year":"2024","unstructured":"Kim JS, Hong S-B, Park K-W, Lee ATC (2024) Psychotic Symptoms in Patients With Major Neurological Diseases. J Clin Neurol 20:153. https:\/\/doi.org\/10.3988\/jcn.2023.0501","journal-title":"J Clin Neurol"},{"key":"3180_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/09540261003589612","volume":"22","author":"MH Kosmidis","year":"2010","unstructured":"Kosmidis MH, Giannakou M, Messinis L, Papathanasopoulos P (2010) Psychotic features associated with multiple sclerosis. Int Rev Psychiatry 22:55\u201366. https:\/\/doi.org\/10.3109\/09540261003589612","journal-title":"Int Rev Psychiatry"},{"key":"3180_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12324","author":"JM Krivinko","year":"2022","unstructured":"Krivinko JM, Erickson SL, MacDonald ML et al (2022) Fingolimod mitigates synaptic deficits and psychosis-like behavior in APP\/PSEN1 mice. Alzheimer\u2019s Dementia: Translational Res Clin Interventions. https:\/\/doi.org\/10.1002\/trc2.12324. 8:","journal-title":"Alzheimer\u2019s Dementia: Translational Res Clin Interventions"},{"key":"3180_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","volume":"12","author":"AO Kruse","year":"2022","unstructured":"Kruse AO, Bustillo JR (2022) Glutamatergic dysfunction in Schizophrenia. Transl Psychiatry 12:500. https:\/\/doi.org\/10.1038\/s41398-022-02253-w","journal-title":"Transl Psychiatry"},{"key":"3180_CR48","doi-asserted-by":"publisher","first-page":"149415","DOI":"10.1016\/j.brainres.2024.149415","volume":"1853","author":"M Kupjetz","year":"2025","unstructured":"Kupjetz M, Wences Chirino TY, Joisten N, Zimmer P (2025) Kynurenine pathway dysregulation as a mechanistic link between cognitive impairment and brain damage: Implications for multiple sclerosis. Brain Res 1853:149415. https:\/\/doi.org\/10.1016\/j.brainres.2024.149415","journal-title":"Brain Res"},{"key":"3180_CR49","doi-asserted-by":"publisher","first-page":"e000060","DOI":"10.1136\/bmjno-2020-000060","volume":"2","author":"AC La Flamme","year":"2020","unstructured":"La Flamme AC, Abernethy D, Sim D et al (2020) Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial. BMJ Neurol Open 2:e000060. https:\/\/doi.org\/10.1136\/bmjno-2020-000060","journal-title":"BMJ Neurol Open"},{"key":"3180_CR50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0006-3223(02)01316-1","volume":"51","author":"SM Lawrie","year":"2002","unstructured":"Lawrie SM, Buechel C, Whalley HC et al (2002) Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 51:1008\u20131011. https:\/\/doi.org\/10.1016\/S0006-3223(02)01316-1","journal-title":"Biol Psychiatry"},{"key":"3180_CR51","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1177\/1352458510365157","volume":"16","author":"S Lo Fermo","year":"2010","unstructured":"Lo Fermo S, Barone R, Patti F et al (2010) Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Scler J 16:742\u2013748. https:\/\/doi.org\/10.1177\/1352458510365157","journal-title":"Multiple Scler J"},{"key":"3180_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.msard.2018.01.012","volume":"20","author":"L Lorefice","year":"2018","unstructured":"Lorefice L, Fenu G, Fois M et al (2018) Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. Mult Scler Relat Disord 20:104\u2013108. https:\/\/doi.org\/10.1016\/j.msard.2018.01.012","journal-title":"Mult Scler Relat Disord"},{"key":"3180_CR53","doi-asserted-by":"publisher","unstructured":"Lovelace MD, Varney B, Sundaram G et al (2016) Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol 7. https:\/\/doi.org\/10.3389\/fimmu.2016.00246","DOI":"10.3389\/fimmu.2016.00246"},{"key":"3180_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"3180_CR55","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/medicina60030376","volume":"60","author":"H Mado","year":"2024","unstructured":"Mado H, B\u0142achut M, Szczegielniak A et al (2024) Risk Factors for Psychiatric Disorders in Patients with Multiple Sclerosis\u2014A Single-Center Study in the Polish Population. Med (B Aires) 60:376. https:\/\/doi.org\/10.3390\/medicina60030376","journal-title":"Med (B Aires)"},{"key":"3180_CR56","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/j.eurpsy.2017.01.2253","volume":"41","author":"M Marinho","year":"2017","unstructured":"Marinho M, Mota-Oliveira M, Marques J, Bragan\u00e7a M (2017) Psychosis Induced by Interferon-\u03b1\u2013A Limitation of Treatment. Eur Psychiatry 41:S236\u2013S236. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.01.2253","journal-title":"Eur Psychiatry"},{"key":"3180_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00726-021-03111-7","volume":"54","author":"V Martinsen","year":"2022","unstructured":"Martinsen V, Kursula P (2022) Multiple sclerosis and myelin basic protein: insights into protein disorder and disease. Amino Acids 54:99\u2013109. https:\/\/doi.org\/10.1007\/s00726-021-03111-7","journal-title":"Amino Acids"},{"key":"3180_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1017\/S0033291704003745","volume":"35","author":"V Murray","year":"2005","unstructured":"McKEE MURRAYV, MILLER I PM, et al (2005) Dimensions and classes of psychosis in a population cohort: a four-class, four-dimension model of schizophrenia and affective psychoses. Psychol Med 35:499\u2013510. https:\/\/doi.org\/10.1017\/S0033291704003745","journal-title":"Psychol Med"},{"key":"3180_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/jnnp-2022-329806","volume":"94","author":"G Menculini","year":"2023","unstructured":"Menculini G, Mancini A, Gaetani L et al (2023) Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction. J Neurol Neurosurg Psychiatry 94:389\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2022-329806","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3180_CR59","doi-asserted-by":"publisher","unstructured":"Mey GM, Mahajan KR, DeSilva TM (2023) Neurodegeneration in multiple sclerosis. WIREs Mech Disease 15. https:\/\/doi.org\/10.1002\/wsbm.1583","DOI":"10.1002\/wsbm.1583"},{"key":"3180_CR60","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1192\/j.eurpsy.2023.2432","volume":"66","author":"B Misiak","year":"2023","unstructured":"Misiak B, Samochowiec J, Kowalski K et al (2023) The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis and schizophrenia. Eur Psychiatry 66:e58. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2432","journal-title":"Eur Psychiatry"},{"key":"3180_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_103_22","volume":"66","author":"S Mitra","year":"2024","unstructured":"Mitra S, Sareen A, Amazan R et al (2024) My sister wants to kill me: A case report and systematic review of literature of co-occurring multiple sclerosis and psychosis. Indian J Psychiatry 66:247\u2013255. https:\/\/doi.org\/10.4103\/indianjpsychiatry.indianjpsychiatry_103_22","journal-title":"Indian J Psychiatry"},{"key":"3180_CR62","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J et al (2025) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24:850\u2013865. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"3180_CR63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jad.2015.08.040","volume":"187","author":"SA Morrow","year":"2015","unstructured":"Morrow SA, Barr J, Rosehart H, Ulch S (2015) Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord 187:142\u2013146. https:\/\/doi.org\/10.1016\/j.jad.2015.08.040","journal-title":"J Affect Disord"},{"key":"3180_CR64","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jnnp-2016-315367","volume":"88","author":"R Murphy","year":"2017","unstructured":"Murphy R, O\u2019Donoghue S, Counihan T et al (2017) Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry 88:697\u2013708. https:\/\/doi.org\/10.1136\/jnnp-2016-315367","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3180_CR66","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ccr3.2781","volume":"8","author":"A Nandy","year":"2020","unstructured":"Nandy A, Nielsen M, Hilt C et al (2020) A case report revealing acute onset psychosis and cognitive impairment as primary manifestation in relapsing-remitting multiple sclerosis. Clin Case Rep 8:833\u2013836. https:\/\/doi.org\/10.1002\/ccr3.2781","journal-title":"Clin Case Rep"},{"key":"3180_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/targets3010010","volume":"3","author":"R Nasim","year":"2025","unstructured":"Nasim R, Nawaz S, Nasim MT (2025) The Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia. Targets 3:10. https:\/\/doi.org\/10.3390\/targets3010010","journal-title":"Targets"},{"key":"3180_CR68","doi-asserted-by":"publisher","DOI":"10.36148\/2284-0249-N455","author":"CP Nibbio Gabriele","year":"2024","unstructured":"Nibbio Gabriele CP, Irene B, Lorenzo et al (2024) Non-pharmacological interventions to improve cognitive impairment and psychosocial functioning in schizophrenia: a critical review. J Psychopathol. https:\/\/doi.org\/10.36148\/2284-0249-N455","journal-title":"J Psychopathol"},{"key":"3180_CR69","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.lpm.2015.02.009","volume":"44","author":"B Nicol","year":"2015","unstructured":"Nicol B, Salou M, Laplaud D-A, Wekerle H (2015) The autoimmune concept of multiple sclerosis. Presse Med 44:e103\u2013e112. https:\/\/doi.org\/10.1016\/j.lpm.2015.02.009","journal-title":"Presse Med"},{"key":"3180_CR70","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"J Oh","year":"2018","unstructured":"Oh J, Vidal-Jordana A, Montalban X (2018) Multiple sclerosis: clinical aspects. Curr Opin Neurol 31:752\u2013759. https:\/\/doi.org\/10.1097\/WCO.0000000000000622","journal-title":"Curr Opin Neurol"},{"key":"3180_CR71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-244X-12-104","volume":"12","author":"B Olabi","year":"2012","unstructured":"Olabi B, Ellison-Wright I, Bullmore E, Lawrie SM (2012) Structural brain changes in first episode Schizophrenia compared with Fronto-Temporal Lobar Degeneration: a meta-analysis. BMC Psychiatry 12:104. https:\/\/doi.org\/10.1186\/1471-244X-12-104","journal-title":"BMC Psychiatry"},{"key":"3180_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13:25\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2016.187","journal-title":"Nat Rev Neurol"},{"key":"3180_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/383108","volume":"2014","author":"ME \u00d6zcan","year":"2014","unstructured":"\u00d6zcan ME, \u0130nce B, Karadeli HH, Asil T (2014) Multiple Sclerosis Presents with Psychotic Symptoms and Coexists with Hypertrophic Cardiomyopathy. Case Rep Neurol Med 2014:1\u20134. https:\/\/doi.org\/10.1155\/2014\/383108","journal-title":"Case Rep Neurol Med"},{"key":"3180_CR74","doi-asserted-by":"publisher","unstructured":"Painold A, Holl A, Letmaier M, Kapfhammer H (2011) Pharmacological treatment of psychosis in multiple sclerosis. Pharmacopsychiatry 44. https:\/\/doi.org\/10.1055\/s-0031-1292526","DOI":"10.1055\/s-0031-1292526"},{"key":"3180_CR75","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1212\/01.wnl.0000178998.95293.29","volume":"65","author":"SB Patten","year":"2005","unstructured":"Patten SB, Svenson LW, Metz LM (2005) Psychotic disorders in MS: Population-based evidence of an association. Neurology 65:1123\u20131125. https:\/\/doi.org\/10.1212\/01.wnl.0000178998.95293.29","journal-title":"Neurology"},{"key":"3180_CR76","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.euroneuro.2014.07.015","volume":"24","author":"E Plitman","year":"2014","unstructured":"Plitman E, Nakajima S, de la Fuente-Sandoval C et al (2014) Glutamate-mediated excitotoxicity in schizophrenia: A review. Eur Neuropsychopharmacol 24:1591\u20131605. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.07.015","journal-title":"Eur Neuropsychopharmacol"},{"key":"3180_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2004.04.019","volume":"223","author":"C Pozzilli","year":"2004","unstructured":"Pozzilli C, Marinelli F, Romano S, Bagnato F (2004) Corticosteroids treatment. J Neurol Sci 223:47\u201351. https:\/\/doi.org\/10.1016\/j.jns.2004.04.019","journal-title":"J Neurol Sci"},{"key":"3180_CR78","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1212\/WNL.41.5.685","volume":"41","author":"SM Rao","year":"1991","unstructured":"Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. Neurology 41:685\u2013691. https:\/\/doi.org\/10.1212\/WNL.41.5.685","journal-title":"Neurology"},{"key":"3180_CR79","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/13651501.2021.1973506","volume":"26","author":"M Sabe","year":"2022","unstructured":"Sabe M, Sentissi O (2022) Psychotic symptoms prior or concomitant to diagnosis of multiple sclerosis: a systematic review of case reports and case series. Int J Psychiatry Clin Pract 26:287\u2013293. https:\/\/doi.org\/10.1080\/13651501.2021.1973506","journal-title":"Int J Psychiatry Clin Pract"},{"key":"3180_CR80","unstructured":"Safferman AZ, Kane JM, Aronowitz JS et al (1994) The use of clozapine in neurologic disorders. J Clin Psychiatry 55 Suppl B :98\u2013101"},{"key":"3180_CR81","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0278-2391(95)90398-4","volume":"53","author":"RG Silva","year":"1995","unstructured":"Silva RG, Tolstunov L (1995) Steroid-induced psychosis. J Oral Maxillofac Surg 53:183\u2013186. https:\/\/doi.org\/10.1016\/0278-2391(95)90398-4","journal-title":"J Oral Maxillofac Surg"},{"key":"3180_CR82","doi-asserted-by":"publisher","unstructured":"Spiegel DR, Ralston M, Sharma SS, Suryadevara P (2023) A Case of Psychosis in a Patient Concurrently Diagnosed With Multiple Sclerosis Treated Successfully With Corticosteroids. Prim Care Companion CNS Disord 25. https:\/\/doi.org\/10.4088\/PCC.22cr03428","DOI":"10.4088\/PCC.22cr03428"},{"key":"3180_CR83","doi-asserted-by":"publisher","first-page":"103522","DOI":"10.1016\/j.msard.2022.103522","volume":"58","author":"\u0395 Stamoula","year":"2022","unstructured":"Stamoula \u0395, Ainatzoglou A, Stamatellos V-P et al (2022) Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. Mult Scler Relat Disord 58:103522. https:\/\/doi.org\/10.1016\/j.msard.2022.103522","journal-title":"Mult Scler Relat Disord"},{"key":"3180_CR84","doi-asserted-by":"crossref","unstructured":"Taylor David, Barnes TRE, Allan Y (2021) The Maudsley prescribing guidelines in psychiatry. Wiley Blackwell, p 956","DOI":"10.1002\/9781119870203"},{"key":"3180_CR85","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391:1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"},{"key":"3180_CR86","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5234\/cnpt.4.6","volume":"4","author":"S Toyooka","year":"2013","unstructured":"Toyooka S, Terao T, Ishii N et al (2013) Clozapine responders may have fewer extrapyramidal symptoms than non-responders: a preliminary report. Clin Neuropsychopharmacol Ther 4:6\u201312. https:\/\/doi.org\/10.5234\/cnpt.4.6","journal-title":"Clin Neuropsychopharmacol Ther"},{"key":"3180_CR87","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.schres.2006.03.021","volume":"85","author":"M Vandergaag","year":"2006","unstructured":"VANDERGAAG M, HOFFMAN T, REMIJSEN M et al (2006) The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model. Schizophr Res 85:280\u2013287. https:\/\/doi.org\/10.1016\/j.schres.2006.03.021","journal-title":"Schizophr Res"},{"key":"3180_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5498\/wjp.v13.i4.161","volume":"13","author":"K Vesic","year":"2023","unstructured":"Vesic K, Gavrilovic A, Mijailovi\u0107 NR, Borovcanin MM (2023) Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses. World J Psychiatry 13:161\u2013170. https:\/\/doi.org\/10.5498\/wjp.v13.i4.161","journal-title":"World J Psychiatry"},{"key":"3180_CR89","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/schbul\/sbt157","volume":"40","author":"H-Q Wu","year":"2014","unstructured":"Wu H-Q, Okuyama M, Kajii Y et al (2014) Targeting Kynurenine Aminotransferase II in Psychiatric Diseases: Promising Effects of an Orally Active Enzyme Inhibitor. Schizophr Bull 40:S152\u2013S158. https:\/\/doi.org\/10.1093\/schbul\/sbt157","journal-title":"Schizophr Bull"},{"key":"3180_CR90","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/brain\/awy287","volume":"141","author":"B Zalc","year":"2018","unstructured":"Zalc B (2018) One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain 141:3482\u20133488. https:\/\/doi.org\/10.1093\/brain\/awy287","journal-title":"Brain"},{"key":"3180_CR91","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"J-P Zhang","year":"2013","unstructured":"Zhang J-P, Gallego JA, Robinson DG et al (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16:1205\u20131218. https:\/\/doi.org\/10.1017\/S1461145712001277","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03180-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:18:07Z","timestamp":1785644287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03180-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3180"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03180-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no financial conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}